Medicine
Griseofulvin MICROSIZE 500 mg tablet
Griseofulvin MICROSIZE 500 mg tablet is a prescription medicine containing Griseofulvin for oral use, marketed by Chartwell RX, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Griseofulvin
- Brand
- Griseofulvin MICROSIZE
- Strength
- 500 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets
- Marketing authorisation holder
- Chartwell RX
- Manufacturers
- Chartwell RXAvet PharmaceuticalsIndia
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D01AA08 Griseofulvin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 September 1971
- Identifiers
- RxCUI 310600DailyMed set ID 1c26d7a6-17d9-4a95-a4ee-cfc5fe6bb95d, 6902a976-b0c5-48a4-8d50-984002be6c3aNDC 23155-865, 62135-496Application ANDA060569
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 62135-496-01 | Chartwell RX | 31 December 2020 |
| 30 tablet in 1 bottle | 62135-496-30 | Chartwell RX | 31 December 2020 |
| 100 tablet in 1 bottle, plastic | 23155-865-01 | Avet PharmaceuticalsIndia | 30 June 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Griseofulvin 500 mg tablet.
Other strengths and forms of Griseofulvin
Clinical summary
Griseofulvin is a tubulin inhibiting agent indicated for the treatment of ringworm infections, tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch). MedsAcross supplies Griseofulvin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GriseofulvinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ultramicrosize Griseofulvin prescribing information (Amneal Pharmaceuticals of New York) · U.S. National Library of Medicine, DailyMed
Need Griseofulvin MICROSIZE 500 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.